Public's perspective on COVID-19 adenovirus vector vaccines after Thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions:A Cross-Sectional Study in six EU member states

Autor: Buhl, Caroline, Jacobsen, Ramune, Almarsdóttir, Anna Birna, van Vliet, Ella, Abtahi, Shahab, Poplavska, Elita, Ribeiro-Vaz , Inês, Kos, Mitja, Čebron Lipovec, Nanča, Dermiki-Gkana, Foteini, Oikonomou, Chara, Kontogiorgis, Christos, Silva , Ana Marta, Barão Sousa Ferreira, Paula, Deligianni, Elena, Kursite, Mirdza, van der Goot, Marloes, Hegger, Ingrid, Leonardo Alves, Teresa

Publikováno v: Buhl, C, Jacobsen, R, Almarsdóttir, A B, van Vliet, E, Abtahi, S, Poplavska, E, Ribeiro-Vaz, I, Kos, M, Čebron Lipovec, N, Dermiki-Gkana, F, Oikonomou, C, Kontogiorgis, C, Silva, A M, Barão Sousa Ferreira, P, Deligianni, E, Kursite, M, van der Goot, M, Hegger, I & Leonardo Alves, T 2023, ' Public's perspective on COVID-19 adenovirus vector vaccines after Thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions : A Cross-Sectional Study in six EU member states ', European Drug Utilization Research Group (EuroDURG) Conference 2023-Sustainability of drug use: equity and innovation, Bologna, Italy, 27/06/2023-30/06/2023 .

Objective: In 2021, thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines from AstraZeneca or Janssen. This study aimed to describe the public’s knowled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2751::9b78862dde5621acc608436c35fa1713
https://curis.ku.dk/portal/da/publications/publics-perspective-on-covid19-adenovirus-vector-vaccines-after-thrombosis-with-thrombocytopenia-syndrome-tts-reports-and-associated-regulatory-actions(2d21df71-2ff6-489c-8fd4-a1a8dde4e0a1).html